Terms: = Kidney tumors AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954
434 results:
1. Segregation, immunohistochemical, molecular and functional analyses classify a novel missense variant in fumarate hydratase (FH) as pathogenic.
Ouchene L; Wilde B; Chan-Pak-Choon F; Camacho Valenzuela J; Brimo F; Witkowski L; Christofk H; Domecq C; Fu L; Weber E; Lemieux Anglin B; Netchiporouk E; Foulkes WD
Genes Chromosomes Cancer; 2024 Feb; 63(2):e23221. PubMed ID: 38682608
[TBL] [Abstract] [Full Text] [Related]
2. Humoral complementomics - exploration of noninvasive complement biomarkers as predictors of renal cancer progression.
Revel M; Rezola Artero M; Hamidi H; Grunenwald A; Blasco L; Vano YA; Marie Oudard S; Sanchez-Salas R; Macek P; Rodriguez Sanchez L; Cathelineau X; Vedié B; Sautes-Fridman C; Herman Fridman W; Roumenina LT; Dragon-Durey MA
Oncoimmunology; 2024; 13(1):2328433. PubMed ID: 38487624
[TBL] [Abstract] [Full Text] [Related]
3. DCLRE1B/Apollo germline mutations associated with renal cell carcinoma impair telomere protection.
Bories C; Lejour T; Adolphe F; Kermasson L; Couvé S; Tanguy L; Luszczewska G; Watzky M; Poillerat V; Garnier P; Groisman R; Ferlicot S; Richard S; Saparbaev M; Revy P; Gad S; Renaud F
Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167107. PubMed ID: 38430974
[TBL] [Abstract] [Full Text] [Related]
4. The clinicopathologic and molecular features, and treatment outcome of fumarate hydratase-deficient renal cell carcinoma: a retrospective comparison with type 2 papillary renal cell carcinoma.
Bai J; Li X; Wen Y; Lu Q; Chen R; Liu R; Shangguan T; Ye Y; Lin J; Cai W; Kang D; Chen J
Aging (Albany NY); 2024 Feb; 16(4):3631-3646. PubMed ID: 38376408
[TBL] [Abstract] [Full Text] [Related]
5. Papillary Renal Cell Carcinoma: Evolving Classification by Combined Morphologic and Molecular Means.
Przybycin CG
Adv Anat Pathol; 2024 May; 31(3):147-156. PubMed ID: 38329413
[TBL] [Abstract] [Full Text] [Related]
6. The Effect of Treatment Intensification on Other-Cause Mortality in Clear-Cell Metastatic Renal Cell Carcinoma Patients.
Incesu RB; Barletta F; Garcia CC; Scheipner L; Morra S; Baudo A; Assad A; Tian Z; Saad F; Shariat SF; Carmignani L; Longo N; Ahyai S; Chun FKH; Briganti A; Tilki D; Graefen M; Karakiewicz PI
Clin Genitourin Cancer; 2024 Apr; 22(2):420-425. PubMed ID: 38307818
[TBL] [Abstract] [Full Text] [Related]
7. Pancreatic Metastasectomy for Secondary Malignancy of the Pancreas: A Single-institution Experience.
Lee O; Yoon SK; Yoon SJ; Kim H; Han IW; Heo JS; Shin SH
Anticancer Res; 2024 Feb; 44(2):703-710. PubMed ID: 38307567
[TBL] [Abstract] [Full Text] [Related]
8. [Expression of programmed cell death ligand 1 and clinicopathological and immunological characteristics in fumarate hydratase-deficient renal cell carcinoma].
Chen S; Ban CR; Zhang XT; Chen YP; Ren CH; Chen H
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):155-161. PubMed ID: 38281783
[No Abstract] [Full Text] [Related]
9. Genetic and clinical characterization of a novel FH founder mutation in families with hereditary leiomyomatosis and renal cell cancer syndrome.
Sánchez-Heras AB; Dámaso E; Castillejo A; Robledo M; Teulé A; Lázaro C; Sánchez-Martínez R; Zúñiga Á; López-Fernández A; Balmaña J; Robles L; Ramon Y Cajal T; Castillejo MI; Ibañez RP; Sevila CM; Sánchez-Mira A; Escandell I; Gómez L; Berbel P; Soto JL
Orphanet J Rare Dis; 2024 Jan; 19(1):26. PubMed ID: 38279137
[TBL] [Abstract] [Full Text] [Related]
10. Referral patterns and genetic testing outcomes in a contemporary hereditary renal cancer clinic.
McFadden J; Hardesty J; Schroeder C; Vance GH; Boris RS
Urol Oncol; 2024 Mar; 42(3):72.e19-72.e25. PubMed ID: 38267302
[TBL] [Abstract] [Full Text] [Related]
11. Update on Selected High-grade Renal Cell Carcinomas of the kidney: FH-deficient, ALK-rearranged, and Medullary Carcinomas.
Chen YB
Adv Anat Pathol; 2024 Mar; 31(2):118-125. PubMed ID: 38145398
[TBL] [Abstract] [Full Text] [Related]
12. Malignant glomus tumor arising in association with a fumarate hydratase-deficient leiomyoma: An unusual collision tumor.
Short EL; Logan SJ; Thangaiah JJ; Folpe AL
J Cutan Pathol; 2024 Apr; 51(4):272-275. PubMed ID: 38140939
[TBL] [Abstract] [Full Text] [Related]
13. The use of Clinicopathological, immunohistochemistry and molecular detection in the diagnosis of fumarate hydratase-deficient uterine leiomyomas.
Zhang X; Wang C; Shen D
Pathol Res Pract; 2024 Jan; 253():154916. PubMed ID: 38029712
[TBL] [Abstract] [Full Text] [Related]
14. Genomic alterations and diagnosis of renal cancer.
Zhang X; Bolck HA; Rupp NJ; Moch H
Virchows Arch; 2024 Feb; 484(2):323-337. PubMed ID: 37999735
[TBL] [Abstract] [Full Text] [Related]
15. Factors influencing the detection rate of fumarate peak in
Pan S; Wang J; Liu G; Zhang J; Song Y; Kong W; Zhou Y; Wu G
Clin Radiol; 2024 Jan; 79(1):e80-e88. PubMed ID: 37923625
[TBL] [Abstract] [Full Text] [Related]
16. Genomic ancestry in kidney cancer: Correlations with clinical and molecular features.
Kotecha RR; Knezevic A; Arora K; Bandlamudi C; Kuo F; Carlo MI; Fitzgerald KN; Feldman DR; Shah NJ; Reznik E; Hakimi AA; Carrot-Zhang J; Mandelker D; Berger M; Lee CH; Motzer RJ; Voss MH
Cancer; 2024 Mar; 130(5):692-701. PubMed ID: 37864521
[TBL] [Abstract] [Full Text] [Related]
17. The Role of Morphology in Predicting Fumarate Hydratase-deficient Uterine Leiomyomas in Young Women.
Bayram A; Bagbudar S; Sozen H; Onder S; Yavuz E
Appl Immunohistochem Mol Morphol; 2023 Nov-Dec 01; 31(10):657-660. PubMed ID: 37751278
[TBL] [Abstract] [Full Text] [Related]
18. Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism.
Valcarcel-Jimenez L; Frezza C
Br J Cancer; 2023 Nov; 129(10):1546-1557. PubMed ID: 37689804
[TBL] [Abstract] [Full Text] [Related]
19. AKR1B10 Is a New Sensitive and Specific Marker for Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Zheng L; Zhang X; Pan X; Huang Z; Zhang M; Xian J; Wei Y; Nie L; Zhang M; Gong J; Chen X; Zhou Q; Zeng H; Chen N
Mod Pathol; 2023 Nov; 36(11):100303. PubMed ID: 37580017
[TBL] [Abstract] [Full Text] [Related]
20. Cryptic splice mutation in the fumarate hydratase gene in patients with clinical manifestations of Hereditary Leiomyomatosis and Renal Cell Cancer.
Crooks DR; Cawthon GM; Fitzsimmons CM; Perez M; Ricketts CJ; Vocke CD; Yang Y; Middelton L; Nielsen D; Schmidt LS; Tandon M; Merino MJ; Ball MW; Meier JL; Batista PJ; Linehan WM
Hum Mol Genet; 2023 Nov; 32(22):3135-3145. PubMed ID: 37561409
[TBL] [Abstract] [Full Text] [Related]
[Next]
